An experimental vaccine against the coronavirus showed encouraging results in very early testing, triggering hoped-for immune responses in eight healthy, middle-aged volunteers, its maker announced Monday.
Study volunteers given either a low or medium dose of the vaccine by Cambridge, Massachusetts-based Moderna Inc. had antibodies similar to those seen in people who have recovered from COVID-19.
The results have not been published and are only from the first of three stages of testing that vaccines and drugs normally undergo.
U.S. government officials have launched a project called “Operation Warp Speed” to develop a vaccine and hopefully have 300 million doses by January.
Health officials have said that if all goes well, studies of a potential vaccine might wrap up by very late this year or early next year.
